Apollomics

Apollomics is a biotechnology company based in Foster City, California. The company employs 37 people and generates $50 million in annual revenue. Apollomics focuses on the discovery and development of oncology combination therapies. Their pipeline consists of ten drug candidates across twelve programs, five of which are in clinical stages. These candidates are categorized into three groups: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Tumor inhibitors target uncontrolled growth signaling pathways in cancer cells, while anti-cancer enhancers aim to boost the effectiveness of other cancer treatments. The immuno-oncology group leverages the body's immune system to fight cancer. Apollomics believes its diverse pipeline of drug candidates, each with different mechanisms of action, will allow them to develop synergistic combination therapies for unmet needs in cancer treatment. For more information, visit Apollomics' website at www.apollomicsinc.com/.